2C-B: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) Internal-linking pass on 2C-B (web-claude addendum, corrected): ~18 first-occurrence links across intro/history/pharmacodynamics/dosing/interactions; redlinks for Alexander Shulgin, DEA, Serotonin syndrome per the amended linking rule |
MDElliottMD (talk | contribs) 2C-B: link the remaining serotonergic-list terms (SNRIs, lithium, dextromethorphan) per pharmacist-claude verification; all 6 now linked |
||
| Line 51: | Line 51: | ||
<titration slug="harm-reduction" author="MDElliottMD" title="Harm reduction considerations"> | <titration slug="harm-reduction" author="MDElliottMD" title="Harm reduction considerations"> | ||
2C-B is a Schedule I controlled substance in the United States with no approved medical use and no legal supply chain that guarantees product identity or purity; in modern markets it is frequently misrepresented as MDMA or substituted with other compounds, including the structurally similar but pharmacologically distinct [[DOB]]. Onset after oral administration is typically 45-75 minutes; the long onset combined with the steep dose-response curve drives a common harm pattern in which inexperienced users redose during the onset window and overshoot the intended dose. Combinations with serotonergic medicines ([[:Category:Selective Serotonin Reuptake Inhibitors (SSRIs)|SSRIs]], SNRIs, [[:Category:Monoamine Oxidase Inhibitors (MAOIs)|MAOIs]], [[Tramadol|tramadol]], lithium, dextromethorphan) carry [[Serotonin syndrome|serotonin syndrome]] risk and should be avoided; combinations with stimulants increase cardiovascular load. The general harm-reduction principles for psychedelic experiences (set, setting, sober companion, advance arrangement of supportive contacts) apply to 2C-B as they do to other 5-HT2A agonists. | 2C-B is a Schedule I controlled substance in the United States with no approved medical use and no legal supply chain that guarantees product identity or purity; in modern markets it is frequently misrepresented as MDMA or substituted with other compounds, including the structurally similar but pharmacologically distinct [[DOB]]. Onset after oral administration is typically 45-75 minutes; the long onset combined with the steep dose-response curve drives a common harm pattern in which inexperienced users redose during the onset window and overshoot the intended dose. Combinations with serotonergic medicines ([[:Category:Selective Serotonin Reuptake Inhibitors (SSRIs)|SSRIs]], [[:Category:Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs)|SNRIs]], [[:Category:Monoamine Oxidase Inhibitors (MAOIs)|MAOIs]], [[Tramadol|tramadol]], [[Lithium|lithium]], [[Dextromethorphan|dextromethorphan]]) carry [[Serotonin syndrome|serotonin syndrome]] risk and should be avoided; combinations with stimulants increase cardiovascular load. The general harm-reduction principles for psychedelic experiences (set, setting, sober companion, advance arrangement of supportive contacts) apply to 2C-B as they do to other 5-HT2A agonists. | ||
</titration> | </titration> | ||